In many ways, it seems like the hardest work for the US Food and Drug Administration during the pandemic is behind it. The agency handled the strain of the clinical requests in the early days, persevered under pressure from President Trump, and has granted emergency use authorization to two vaccines, with more expected in the months to come.
But that rosy outlook doesn't include the many difficult choices the agency must make to help the biopharma industry recover from the pandemic and the country prepare for the next one
